Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

High BMI is a well-known risk factor for the development and recurrence of several solid tumours, including CRC. Obesity is associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab is the main targeted therapy for inhibiting tumour angiogenesis by blocking the VEGF/...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Faruk Aykan, N., Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Ciftci, Rumeysa, Karabulut, Senem, Sakar, Burak, Disci, Rian
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2013
Schlagworte:
Original Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755215/
https://ncbi.nlm.nih.gov/pubmed/23921648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-013-0679-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge